Mumbai, India – October 1, 2014 - Belonging to close group of related blood cancers, the myeloproliferative neoplasms is the condition in which the bone marrow cells that produces blood cells start functioning abnormally. This results in the patient suffering from excessive fibrous tissue formation in the bone marrow resulting in severe anemia, fatigue, weakness and enlarged spleen and liver. Even if the condition occurs on their own, the primary myelofibrosis can lead to myelofibrosis include polycythemia vera (PV) and essential thrombocythemia (ET). As of the current time, there are no available drug therapy that can cure this condition which makes it important to develop medicines in the fracture movement of MF that can solve the problem or at least improve the quality of the life of the patient.

The Fracture - Pipeline Review, H2 2014 provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects.

Treatment therapies available for patients
Even if stem cell transplantation has helped to curb the suffering, the procedure is still very risky in older MF patients which may also have other health programs. This means that allogenic stem cell transplantation is usually appropriate only for a smaller subset of younger patients which is typically less than 5% of younger patients. Others who do not have any symptoms or does not have anemia, the enlarged spleen and other complications are not treated especially when the condition remains suppressed for long time. However, it is imperative that patients with such symptoms need to be monitored regularly through medical checkups and examinations to keep a track of the progression of the disease.

Since every patient has a different medical situation, it is important that doctors evaluate patients and prescribe medicines or treatment accordingly. There are some professionals who use a prognostic scoring system to plan a risk adapted treatment strategy that will only include observation. Others use JAK inhibitors and pomalidomide, drug therapies, reduced intensity allogenic stem cell transplation, splenectomy or radiation therapy. However, all these treatments have their own risk factors include anemia, red blood cell transfusion, leukocytosis, unfavorable karyotype and constitutional symptoms. All these factors have increased demand of clinical trials.

For further insights, click here

About Research on Global Markets
Research on Global Markets is a leading source for market research on various sectors globally, offering premium research content from worldwide publishers of market research reports. Our database hosts premium market research content developed by global publishers. It offers premium industry research reports, company profiles and country briefs. We have a dedicated team of research professionals who can facilitate, in an unbiased manner, the process of identifying appropriate market research reports that are targeted to fulfill all your information-related requirements.

For more details on the content of each report and ordering information, please contact:
Phone: +91 22 4098 7600
E-Mail:[email protected]